Intensive-Care Patients Need Treatment to Stop Deadly Bug

Intensive-Care Patients Need Treatment to Stop Deadly Bug

Disinfecting all intensive-care patients to remove potentially deadly bacteria can prevent infections better than testing for a superbug and targeting only those who carry it, researchers said.

Patients in hospital intensive-care units are particularly vulnerable, weakened so that normally harmless microbes can make them ill and sensitive to acquiring infections from others. Hospitals in the U.S. typically test for bacteria like methicillin-resistant Staphylococcus aureus when patients are admitted and isolate those who show signs of harboring it to stop the spread.The approach doesn’t help the carriers, according to research published today in the New England Journal of Medicine that shows it also isn’t ideal for preventing more infections. Instead, bathing every patient with anti-microbial soap and using a topical antibiotic ointment for five days to kill reservoirs in the nose reduced infection rates 44 percent, the study found.

“This is the answer to a long-debated question: Do we target every superbug one by one or try to protect a certain patient group from all disease,” Susan Huang, the lead researcher and associate professor in infectious disease at the University of California, Irvine, School of Medicine, said in a telephone interview. “Targeting high-risk patients seems to be the better way to go. Universal decontamination is the easiest and most effective way to prevent infection.”

HCA Hospitals

The research involved 74,256 patients at 43 hospitals across the country owned by Nashville, Tennessee-based HCA Holdings Inc. (HCA), the largest for-profit U.S. hospital chain. The researchers examined three methods to control hospital-acquired infections, a main cause of preventable illness and death. Reducing infections has become a focus of the U.S. government, which put policies in place to penalize institutions with high infection levels.

The researchers found no benefit in preventing bloodstream infections with the most commonly used approach of testing and isolating patients with MRSA. Testing and treating only those who carried the bacteria was more effective, though not as much as universally treating patients to eradicate all types of microbes, regardless of whether they showed signs of MRSA, the investigators found.

The finding should have immediate implications, Huang said. Each MRSA infection can boost health-care costs by $20,000 as doctors fight the bug and work to stop it from spreading. The universal treatment approach was relatively inexpensive and yielded an unexpectedly dramatic benefit, she said.

All Infections

“I really believe that this should be adopted by many, if not most hospitals as a way to reduce infections from all pathogens, not just these superbugs,” she said.

HCA has started using the approach at its hospitals, which account for about 5 percent of all inpatient care in the U.S., she said.

The patients were treated with intranasal mupirocin, a generic antibiotic, for five days and bathed with cloths that contained the antimicrobial drug chlorhexidine for their entire stay. The approach would prevent 1 bloodstream infection for every 54 patients who were treated, the researchers calculated. The reduction in MRSA infections was similar to the decrease in all infections, though it wasn’t statistically significant.

The study resolves one of the most controversial issues in infection control for the past decade and should lead to the repeal of laws in nine states requiring MRSA screening, said Michael Edmond and Richard Wenzel from Virginia Commonwealth University School of Medicine’s division of infectious diseases in Richmond.

Isolation ‘Unfriendly’

Patients shouldn’t be isolated, an “unfriendly” practice that can interfere with care, they wrote in an editorial accompanying the study.

The findings should bolster the argument for treating all patients “to control not only the pathogens of today but those of tomorrow as well,” they wrote. They also cautioned against universal use of mupirocin because resistance can develop, making the drug less effective.

Huang agreed that doctors should closely monitor patients to ensure drug resistance doesn’t develop. Since the medicine isn’t currently used to treat active infections, however, she said its use doesn’t have to be limited.

“These agents aren’t used to treat disease,” she said. “These are topical agents to get things off the skin and out of the nose. We haven’t lost an antibiotic we would traditionally use if resistance develops.”

The Agency for Healthcare Research and the U.S. Centers for Disease Control and Prevention funded the study.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at

About bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (, the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: